In:
Frontiers in Immunology, Frontiers Media SA, Vol. 14 ( 2023-6-2)
Kurzfassung:
JAK inhibitors treat various autoimmune diseases, but an updated systematic review in treating alopecia areata is currently lacking. Objective Evaluate the specific efficacy and safety of JAK inhibitors in alopecia areata by systematic review and meta-analysis. Methods Eligible studies in PubMed, Embase, Web of Science, and Clinical Trials up to May 30, 2022, were searched. We enrolled in randomized controlled trials and observational studies of applying JAK inhibitors in alopecia areata. Results 6 randomized controlled trials with 1455 patients exhibited SALT 50 (odd ratio [OR], 5.08; 95% confidence interval [CI] , 3.49-7.38), SALT 90 (OR, 7.40; 95% CI, 4.34-12.67) and change in SALT score (weighted mean difference [WSD], 5.55; 95% CI, 2.60-8.50) compared to the placebo. The proportion of 26 observational studies with 563 patients of SALT 5 was 0.71(95% CI, 0.65-0.78), SALT 50 was 0.54(95% CI 0.46-0.63), SALT 90 was 0.33(95% CI, 0.24-0.42), and SALT score (WSD, -2.18; 95% CI, -3.12 to -1.23) compared with baseline. Any adverse effects occurred in 921 of 1508 patients; a total of 30 patients discontinued the trial owing to adverse reactions. Limitations Few randomized controlled trials met the inclusion criteria and insufficiency of eligible data. Conclusion JAK inhibitors are effective in alopecia areata, although associated with an increased risk.
Materialart:
Online-Ressource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2023.1195858
DOI:
10.3389/fimmu.2023.1195858.s001
Sprache:
Unbekannt
Verlag:
Frontiers Media SA
Publikationsdatum:
2023
ZDB Id:
2606827-8
